Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound
Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficie...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/19/6018 |
| _version_ | 1827680645412814848 |
|---|---|
| author | Tsung-Ju Li Ting-Wei Lin Shih-Pei Wu Hsin-Tung Chu Yu-Hsuan Kuo Jeng-Fong Chiou Long-Sheng Lu Chin-Chu Chen |
| author_facet | Tsung-Ju Li Ting-Wei Lin Shih-Pei Wu Hsin-Tung Chu Yu-Hsuan Kuo Jeng-Fong Chiou Long-Sheng Lu Chin-Chu Chen |
| author_sort | Tsung-Ju Li |
| collection | DOAJ |
| description | Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficiently expands CTC from patients to test <i>Antrodia Cinnamomea</i> mycelium-derived bioactive compounds. Three ACM-derived bioactive compounds were evaluated for tumor chemosensitization characteristics. Significant and consistent cytotoxic/5-FU sensitizing effects of GKB202 were found on 8 different patient-derived tumors. Acute toxicity profile and hepatic metabolism of GKB202 in rats suggest GKB202 is rapidly cleared by liver and is well tolerated up to the dose of 20 mg/kg. This comprehensive study provides new evidence that liquid fermentation of <i>Antrodia cinnamomea</i> mycelium (<i>ACM</i>) contains bioactive compounds that lead to effective control of CTC, especially when combined with 5-FU. Together, these data suggest ACM-derived GKB202 may be considered for further clinical investigation in the context of 5-FU-based combination therapy. |
| first_indexed | 2024-03-10T06:54:33Z |
| format | Article |
| id | doaj.art-edf5e642b2ca47febd56bf887f48a489 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T06:54:33Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-edf5e642b2ca47febd56bf887f48a4892023-11-22T16:36:06ZengMDPI AGMolecules1420-30492021-10-012619601810.3390/molecules26196018Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive CompoundTsung-Ju Li0Ting-Wei Lin1Shih-Pei Wu2Hsin-Tung Chu3Yu-Hsuan Kuo4Jeng-Fong Chiou5Long-Sheng Lu6Chin-Chu Chen7Biotech Research Institute, Grape King Bio, Taoyuan 32542, TaiwanBiotech Research Institute, Grape King Bio, Taoyuan 32542, TaiwanCancerFree Biotech Ltd., Taipei City 106, TaiwanBiotech Research Institute, Grape King Bio, Taoyuan 32542, TaiwanBiotech Research Institute, Grape King Bio, Taoyuan 32542, TaiwanDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, TaiwanDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, TaiwanBiotech Research Institute, Grape King Bio, Taoyuan 32542, TaiwanOral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficiently expands CTC from patients to test <i>Antrodia Cinnamomea</i> mycelium-derived bioactive compounds. Three ACM-derived bioactive compounds were evaluated for tumor chemosensitization characteristics. Significant and consistent cytotoxic/5-FU sensitizing effects of GKB202 were found on 8 different patient-derived tumors. Acute toxicity profile and hepatic metabolism of GKB202 in rats suggest GKB202 is rapidly cleared by liver and is well tolerated up to the dose of 20 mg/kg. This comprehensive study provides new evidence that liquid fermentation of <i>Antrodia cinnamomea</i> mycelium (<i>ACM</i>) contains bioactive compounds that lead to effective control of CTC, especially when combined with 5-FU. Together, these data suggest ACM-derived GKB202 may be considered for further clinical investigation in the context of 5-FU-based combination therapy.https://www.mdpi.com/1420-3049/26/19/6018<i>Antrodia Cinnamomea</i> myceliumACMcirculating tumor cellspatient-derived organoid5-FU |
| spellingShingle | Tsung-Ju Li Ting-Wei Lin Shih-Pei Wu Hsin-Tung Chu Yu-Hsuan Kuo Jeng-Fong Chiou Long-Sheng Lu Chin-Chu Chen Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound Molecules <i>Antrodia Cinnamomea</i> mycelium ACM circulating tumor cells patient-derived organoid 5-FU |
| title | Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound |
| title_full | Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound |
| title_fullStr | Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound |
| title_full_unstemmed | Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound |
| title_short | Patient-Derived Tumor Chemosensitization of GKB202, an <i>Antrodia Cinnamomea</i> Mycelium-Derived Bioactive Compound |
| title_sort | patient derived tumor chemosensitization of gkb202 an i antrodia cinnamomea i mycelium derived bioactive compound |
| topic | <i>Antrodia Cinnamomea</i> mycelium ACM circulating tumor cells patient-derived organoid 5-FU |
| url | https://www.mdpi.com/1420-3049/26/19/6018 |
| work_keys_str_mv | AT tsungjuli patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT tingweilin patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT shihpeiwu patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT hsintungchu patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT yuhsuankuo patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT jengfongchiou patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT longshenglu patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound AT chinchuchen patientderivedtumorchemosensitizationofgkb202aniantrodiacinnamomeaimyceliumderivedbioactivecompound |